Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates | Zendy

Edward E. Walsh | Zendy; Robert W. Frenck | Zendy; Ann R. Falsey | Zendy; Nicholas Kitchin | Zendy; Judith Absalon | Zendy; Alejandra Gurtman | Zendy; Stephen Lockhart | Zendy; Kathleen M. Neuzil | Zendy; Mark J. Mulligan | Zendy; Ruth Bailey | Zendy; Kena A. Swanson | Zendy; Ping Li | Zendy; Kenneth Koury | Zendy; Warren V. Kalina | Zendy; David Cooper | Zendy; Camila R. Fontes-Garfias | Zendy; PeiYong Shi | Zendy; Özlem Türeci | Zendy; Kristin Tompkins | Zendy; Kirsten E. Lyke | Zendy; Vanessa Raabe | Zendy; Philip R. Dormitzer | Zendy; Kathrin U. Jansen | Zendy; Uǧur Şahin | Zendy; William C. Gruber | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Author(s) -

Edward E. Walsh,

Robert W. Frenck,

Ann R. Falsey,

Nicholas Kitchin,

Judith Absalon,

Alejandra Gurtman,

Stephen Lockhart,

Kathleen M. Neuzil,

Mark J. Mulligan,

Ruth Bailey,

Kena A. Swanson,

Ping Li,

Kenneth Koury,

Warren V. Kalina,

David Cooper,

Camila R. Fontes-Garfias,

PeiYong Shi,

Özlem Türeci,

Kristin Tompkins,

Kirsten E. Lyke,

Vanessa Raabe,

Philip R. Dormitzer,

Kathrin U. Jansen,

Uǧur Şahin,

William C. Gruber

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2027906

Subject(s) - immunogenicity , covid-19 , virology , computational biology , medicine , biology , immunology , outbreak , antigen , infectious disease (medical specialty) , disease

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and the resulting disease, coronavirus disease 2019 (Covid-19), have spread to millions of persons worldwide. Multiple vaccine candidates are under development, but no vaccine is currently available. Interim safety and immunogenicity data about the vaccine candidate BNT162b1 in younger adults have been reported previously from trials in Germany and the United States.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research